Loading...
Market
Will the anti-IL-11 antibody therapy enter Phase II clinical trials by December 31, 2024?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
Clinical trial registries and announcements from the company developing the therapy
Story
New Anti-Ageing Therapy Extends Lifespan of Mice by 25%, Reduces Cancer
Jul 18, 2024, 01:06 AM
A new anti-ageing therapy has been shown to extend the lifespan of mice by nearly 25%, according to a study published in Nature. The therapy involves inhibiting interleukin-11 (IL-11), a pro-inflammatory cytokine, which leads to significant health benefits and increased longevity in mice. Both genetic deletion and an anti-IL-11 drug were effective in extending the lifespan of male mice by 22.5% and female mice by 25%. The treated mice, dubbed 'supermodel grannies' due to their youthful appearance, were healthier, stronger, and had fewer age-related health problems. The therapy also reduced the incidence of cancer. This breakthrough has raised hopes for similar anti-ageing treatments in humans, with the anti-IL-11 antibody already in early clinical trials for other conditions such as lung fibrosis.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Completed with positive results • 25%
Completed with negative results • 25%
Not completed • 25%
Unknown/Other • 25%
Approved by FDA • 25%
Approved by EMA • 25%
Approved by another regulatory body • 25%
Not approved by any major regulatory body • 25%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Approved • 25%
Yes • 50%
No • 50%
Phase 1 • 25%
Phase 2 • 25%
Phase 3 • 25%
Phase 4 • 25%
Yes • 50%
No • 50%
Initiated before January 1, 2025 • 25%
Initiated between January 1, 2025 and March 31, 2025 • 25%
Initiated between April 1, 2025 and June 30, 2025 • 25%
Not initiated by June 30, 2025 • 25%